| Product Code: ETC070004 | Publication Date: Jul 2023 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The Thailand Contract Cell and Gene Therapy Manufacturing Market was estimated at USD 108 Million in 2025 and is projected to reach USD 123 Million by 2032, growing at a CAGR of 1.9% from 2026 to 2032. This growth is largely driven by the increasing prevalence of genetic disorders and chronic diseases in Thailand, which are prompting biopharmaceutical companies to seek advanced and tailored therapeutic solutions. The local contract manufacturing organizations (CMOs) are meeting this demand through innovative and specialized services, establishing Thailand as an emerging hub for cell and gene therapy development.
This graph highlights how the Thailand Contract Cell and Gene Therapy Manufacturing Market has steadily grown over the years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | -3.5% | Growing renewable energy integration projects |
| 2022 | 2.6% | Growing urbanization and commercial development |
| 2023 | 3.0% | Growing renewable energy integration projects |
| 2024 | 2.7% | Growing urbanization and commercial development |
| 2025 | 3.6% | Rapid growth in telecom and data center sectors |
| 2026 | 3.1% | Expansion of commercial construction activities |
| 2027 | 2.5% | Expansion of manufacturing activities |
| 2028 | 2.8% | Increasing industrial infrastructure investments |
| 2029 | 2.5% | Increasing smart city development projects |
| 2030 | 3.0% | Increasing industrial automation investments |
| 2031 | 2.9% | Rising electricity demand across industries |
| 2032 | 2.7% | Increasing adoption of advanced technologies |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
While the market has witnessed significant momentum, the trajectory ahead indicates a transformative phase fueled by advancements in biomanufacturing technologies and a growing emphasis on personalized medicine. With a robust pipeline of clinical trials and regulatory approvals, the Thailand Contract Cell and Gene Therapy Manufacturing Market is positioned for substantial growth, further enhancing the country’s stature on the global stage.
Thailand’s contract cell and gene therapy sector is at a pivotal juncture, where strategic collaborations between CMOs and academic institutions are fostering innovation and technology transfer. As these partnerships strengthen, they are likely to enhance the capabilities and efficiencies of local manufacturers, thereby stimulating further investment and market expansion.
Despite its promising outlook, the Thailand Contract Cell and Gene Therapy Manufacturing Market faces several restraints. The complex and costly nature of the manufacturing processes involved in cell and gene therapies presents a significant challenge. Compliance with stringent regulatory standards further complicates operations, requiring CMOs to invest heavily in state-of-the-art technologies and a highly skilled workforce. Additionally, a shortage of experienced professionals in this specialized field hampers the ability of companies to scale their operations effectively, which could limit market growth in the near term.
The market is currently shaped by several key trends. First, the integration of automation and digital technologies in manufacturing processes is enhancing efficiency and reducing costs. Furthermore, there is a significant shift towards personalized and precision medicine, compelling CMOs to adapt their services to meet specific therapeutic needs. Additionally, increased investment in research and development is leading to the emergence of novel cell and gene therapy products, propelling the market forward.
The Thailand Contract Cell and Gene Therapy Manufacturing Market is rife with growth opportunities. The increasing number of clinical trials and the anticipated approvals of new therapies are set to boost demand for contract manufacturing services. Moreover, as biopharmaceutical companies look to expedite their development timelines, there is a growing trend toward outsourcing, creating a fertile ground for CMOs to expand their service offerings. Enhanced international collaborations and partnerships are also likely to drive innovation and open new avenues for market growth.
The Thai government has recognized the importance of biopharmaceutical manufacturing, implementing policies to enhance the capabilities of the sector. Initiatives focused on funding research and development, along with supportive regulations for clinical trials, are in place to bolster local manufacturing. Additionally, there are programs designed to encourage partnerships between CMOs and academic institutions, fostering an environment conducive to innovation and technology transfer in the field of cell and gene therapies.
Looking ahead to 2026-2032, the Thailand Contract Cell and Gene Therapy Manufacturing Market is poised for sustained growth. Driven by a robust pipeline of therapies and increasing investment in manufacturing infrastructure, the market will likely evolve to meet emerging healthcare demands. As the global landscape for cell and gene therapies continues to expand, Thailand is expected to solidify its position as a competitive manufacturing hub, leveraging its skilled workforce and favorable regulatory environment to attract further investment.
Recent developments in the Thailand Contract Cell and Gene Therapy Manufacturing Market have focused on strengthening local production capabilities and enhancing technological innovations. Efforts are underway to increase collaboration between CMOs and research institutions, aimed at expediting the development of new therapies. Additionally, industry stakeholders are actively seeking ways to improve supply chain resiliency and streamline regulatory processes, all of which are integral to sustaining growth in the sector.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Thailand Contract Cell and Gene Therapy Manufacturing Market Overview |
3.1 Thailand Country Macro Economic Indicators |
3.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, 2022 & 2032F |
3.3 Thailand Contract Cell and Gene Therapy Manufacturing Market - Industry Life Cycle |
3.4 Thailand Contract Cell and Gene Therapy Manufacturing Market - Porter's Five Forces |
3.5 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Vector, 2022 & 2032F |
3.6 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Indication, 2022 & 2032F |
4 Thailand Contract Cell and Gene Therapy Manufacturing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Thailand Contract Cell and Gene Therapy Manufacturing Market Trends |
6 Thailand Contract Cell and Gene Therapy Manufacturing Market, By Types |
6.1 Thailand Contract Cell and Gene Therapy Manufacturing Market, By Vector |
6.1.1 Overview and Analysis |
6.1.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Vector, 2022-2032F |
6.1.3 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Viral Vector, 2022-2032F |
6.1.4 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Non-viral Vector, 2022-2032F |
6.2 Thailand Contract Cell and Gene Therapy Manufacturing Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Cancer, 2022-2032F |
6.2.3 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Neurological Diseases, 2022-2032F |
6.2.4 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Hepatological Diseases, 2022-2032F |
6.2.5 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Others, 2022-2032F |
7 Thailand Contract Cell and Gene Therapy Manufacturing Market Import-Export Trade Statistics |
7.1 Thailand Contract Cell and Gene Therapy Manufacturing Market Export to Major Countries |
7.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Imports from Major Countries |
8 Thailand Contract Cell and Gene Therapy Manufacturing Market Key Performance Indicators |
9 Thailand Contract Cell and Gene Therapy Manufacturing Market - Opportunity Assessment |
9.1 Thailand Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Vector, 2022 & 2032F |
9.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Indication, 2022 & 2032F |
10 Thailand Contract Cell and Gene Therapy Manufacturing Market - Competitive Landscape |
10.1 Thailand Contract Cell and Gene Therapy Manufacturing Market Revenue Share, By Companies, 2025 |
10.2 Thailand Contract Cell and Gene Therapy Manufacturing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here